| Nome |
# |
|
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression, file 114fed17-b83b-46da-91ef-667cebee5d84
|
308
|
|
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting, file e4233f17-5bd2-2860-e053-6605fe0a460a
|
115
|
|
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience, file e4233f16-1a32-2860-e053-6605fe0a460a
|
100
|
|
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage, file e4233f16-15f4-2860-e053-6605fe0a460a
|
84
|
|
null, file e4233f17-03df-2860-e053-6605fe0a460a
|
84
|
|
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence, file e4233f17-a28b-2860-e053-6605fe0a460a
|
62
|
|
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer, file e4233f17-d309-2860-e053-6605fe0a460a
|
39
|
|
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody., file e4233f16-3733-2860-e053-6605fe0a460a
|
29
|
|
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts, file e4233f16-3962-2860-e053-6605fe0a460a
|
24
|
|
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin, file e4233f15-d34c-2860-e053-6605fe0a460a
|
23
|
|
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial., file e4233f16-15f7-2860-e053-6605fe0a460a
|
23
|
|
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors, file e4233f16-27e1-2860-e053-6605fe0a460a
|
23
|
|
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome, file e4233f16-2338-2860-e053-6605fe0a460a
|
22
|
|
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells, file e4233f16-ec7e-2860-e053-6605fe0a460a
|
22
|
|
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable, file e4233f17-0908-2860-e053-6605fe0a460a
|
22
|
|
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma, file e4233f17-d007-2860-e053-6605fe0a460a
|
22
|
|
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy, file e4233f16-233a-2860-e053-6605fe0a460a
|
21
|
|
Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?, file e4233f16-1820-2860-e053-6605fe0a460a
|
20
|
|
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure, file e4233f18-556b-2860-e053-6605fe0a460a
|
20
|
|
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report, file e4233f16-2fa4-2860-e053-6605fe0a460a
|
19
|
|
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials, file e4233f17-03db-2860-e053-6605fe0a460a
|
19
|
|
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag, file e4233f16-1dd0-2860-e053-6605fe0a460a
|
18
|
|
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer, file e4233f16-27e8-2860-e053-6605fe0a460a
|
18
|
|
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives, file e4233f17-a289-2860-e053-6605fe0a460a
|
18
|
|
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives, file e4233f18-a038-2860-e053-6605fe0a460a
|
18
|
|
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status, file e4233f16-27f8-2860-e053-6605fe0a460a
|
17
|
|
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study, file e4233f17-747f-2860-e053-6605fe0a460a
|
17
|
|
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation", file e4233f17-9200-2860-e053-6605fe0a460a
|
17
|
|
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice, file e4233f18-a98b-2860-e053-6605fe0a460a
|
17
|
|
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma, file e4233f16-2852-2860-e053-6605fe0a460a
|
16
|
|
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study, file e4233f16-7764-2860-e053-6605fe0a460a
|
16
|
|
A multidisciplinary group for prostate cancer management: A single institution experience, file e4233f16-84b9-2860-e053-6605fe0a460a
|
16
|
|
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis, file e4233f16-2335-2860-e053-6605fe0a460a
|
15
|
|
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting, file e4233f17-8622-2860-e053-6605fe0a460a
|
15
|
|
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study, file e4233f16-d1b8-2860-e053-6605fe0a460a
|
14
|
|
Treatment of metastatic colorectal cancer patients 75 years old in clinical practice: A multicenter analysis, file e4233f16-26b7-2860-e053-6605fe0a460a
|
13
|
|
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression, file e4233f18-940d-2860-e053-6605fe0a460a
|
13
|
|
null, file e4233f15-91e1-2860-e053-6605fe0a460a
|
12
|
|
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey, file e4233f15-caa2-2860-e053-6605fe0a460a
|
12
|
|
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial, file e4233f16-27ed-2860-e053-6605fe0a460a
|
12
|
|
Eribulin in triple negative metastatic breast cancer: Critic interpretation of current evidence and projection for future scenarios, file e4233f17-a1a0-2860-e053-6605fe0a460a
|
12
|
|
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: Current evidence and literature-based meta-analysis of randomized trials, file e4233f18-3daf-2860-e053-6605fe0a460a
|
12
|
|
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study, file 3a4b6c7c-5bce-4ec1-8fd7-7ffb4638d71b
|
11
|
|
null, file e4233f16-fcb8-2860-e053-6605fe0a460a
|
11
|
|
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study, file e4233f18-38f3-2860-e053-6605fe0a460a
|
11
|
|
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score, file e4233f18-d188-2860-e053-6605fe0a460a
|
11
|
|
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study, file e4233f19-3bdd-2860-e053-6605fe0a460a
|
11
|
|
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies, file e4233f15-0650-2860-e053-6605fe0a460a
|
10
|
|
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis, file e4233f15-47bf-2860-e053-6605fe0a460a
|
10
|
|
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file eefa9c0c-0a62-48a3-b14b-64ceadad9992
|
10
|
|
Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment, file e4233f16-233d-2860-e053-6605fe0a460a
|
9
|
|
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study, file e4233f16-3e89-2860-e053-6605fe0a460a
|
9
|
|
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting, file c5838e51-8b69-42be-b4e0-7c0567e424dd
|
8
|
|
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer, file e4233f15-0a20-2860-e053-6605fe0a460a
|
8
|
|
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment, file e4233f15-51d9-2860-e053-6605fe0a460a
|
8
|
|
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review, file e4233f15-babe-2860-e053-6605fe0a460a
|
8
|
|
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer, file e4233f16-1724-2860-e053-6605fe0a460a
|
8
|
|
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial, file 0886a523-3310-467a-b37c-fcddef01c985
|
7
|
|
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting, file 26826aa7-b457-45c4-ad25-a9a93cb38bfd
|
7
|
|
Alectinib induced regression of renal and hepatic cysts caused by crizotinib, file 5e173c4c-077d-4a35-a612-8319748f2396
|
7
|
|
Outcomes of HER2-positive early breast cancer patients
in the pre-trastuzumab and trastuzumab eras: a real-world
multicenter observational analysis. The RETROHER study, file e4233f15-1297-2860-e053-6605fe0a460a
|
6
|
|
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey, file e4233f15-3d95-2860-e053-6605fe0a460a
|
5
|
|
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies, file e4233f16-27f3-2860-e053-6605fe0a460a
|
5
|
|
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?, file e4233f16-22df-2860-e053-6605fe0a460a
|
4
|
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e4233f16-cc38-2860-e053-6605fe0a460a
|
4
|
|
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis, file e4233f16-d194-2860-e053-6605fe0a460a
|
4
|
|
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors, file e4233f15-00ab-2860-e053-6605fe0a460a
|
3
|
|
New Targets for Therapy in Pancreatic Cancer, file e4233f15-00ac-2860-e053-6605fe0a460a
|
3
|
|
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction, file e4233f16-2340-2860-e053-6605fe0a460a
|
3
|
|
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience, file e4233f17-03d7-2860-e053-6605fe0a460a
|
3
|
|
null, file 7aac849c-2fda-48fd-a316-da3cd16bf4c0
|
2
|
|
90K (Mac-2 BP) and galectins in tumor progression and metastasis., file e4233f14-ee19-2860-e053-6605fe0a460a
|
2
|
|
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study., file e4233f14-ee2a-2860-e053-6605fe0a460a
|
2
|
|
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer, file e4233f15-6e57-2860-e053-6605fe0a460a
|
2
|
|
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab, file e4233f16-98d4-2860-e053-6605fe0a460a
|
2
|
|
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation, file e4233f17-6ad0-2860-e053-6605fe0a460a
|
2
|
|
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events, file e4233f17-8ede-2860-e053-6605fe0a460a
|
2
|
|
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study, file e4233f18-9188-2860-e053-6605fe0a460a
|
2
|
|
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence, file aa4e8d13-0b2d-4534-b9ec-e537bcea210e
|
1
|
|
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival, file e4233f14-edac-2860-e053-6605fe0a460a
|
1
|
|
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer, file e4233f14-f0fb-2860-e053-6605fe0a460a
|
1
|
|
Unknown primary tumors, file e4233f14-f862-2860-e053-6605fe0a460a
|
1
|
|
Tyrosine kinase inhibitors, file e4233f14-fcb1-2860-e053-6605fe0a460a
|
1
|
|
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice., file e4233f15-0176-2860-e053-6605fe0a460a
|
1
|
|
Tumor-derived microvesicles: The metastasomes., file e4233f15-079e-2860-e053-6605fe0a460a
|
1
|
|
Triple positive breast cancer: A distinct subtype?, file e4233f15-0e41-2860-e053-6605fe0a460a
|
1
|
|
TREATMENT (T) OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) ≥75 YEARS (Y) OLD IN CLINICAL PRACTICE: A MULTICENTER ANALYSIS, file e4233f15-0e42-2860-e053-6605fe0a460a
|
1
|
|
Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer, file e4233f15-1291-2860-e053-6605fe0a460a
|
1
|
|
Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13-ambra study, file e4233f17-021a-2860-e053-6605fe0a460a
|
1
|
|
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study, file e4233f17-6224-2860-e053-6605fe0a460a
|
1
|
|
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation, file e4233f18-7b1d-2860-e053-6605fe0a460a
|
1
|
| Totale |
1.652 |